Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Cermelli, Silvia ^a   Ruggieri, Anna ^a,b   Marrero, Jorge A ^c   Ioannou, George N ^d   Beretta, Laura ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 122; MICRORNA 16; MICRORNA 21; MICRORNA 34A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN122 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NUCLEIC ACID ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS REPLICATION; BLOOD; CASE CONTROL STUDY; FATTY LIVER; GENETICS; HOSPITALIZATION;

HEPATITIS C VIRUS;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; MICRORNAS; SEVERITY OF ILLNESS INDEX;

EID: 80052008851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023937     Document Type: Article

References (37)

1. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
2. Kosaka N, Iguchi H, Ochiya T, (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092.
3. Brase JC, Wuttig D, Kuner R, Sultmann H, (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9: 306.
4. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
5. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
6. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, et al. (2010) Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 52: 1431-1442.
7. Lewis AP, Jopling CL, (2010) Regulation and biological function of the liver-specific miR-122. Biochem Soc Trans 38: 1553-1557.
8. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, et al. (2007) Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 104: 12884-12889.
9. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, et al. (2008) microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 27: 3300-3310.
10. Jangra RK, Yi M, Lemon SM, (2010) Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 84: 6615-6625.
11. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS, (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
12. Zeng C, Wang R, Li D, Lin XJ, Wei QK, et al. (2010) A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 52: 1702-1712.
13. Filipowicz W, Grosshans H, (2011) The liver-specific microRNA miR-122: biology and therapeutic potential. Prog Drug Res 67: 221-238.
14. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. (2008) MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232.
15. Aqeilan RI, Calin GA, Croce CM, (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
16. Garzon R, Marcucci G, Croce CM, (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
17. Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, et al. (2011) Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One 6: e15304.
18. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, et al. (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727-1736.
19. Hermeking H, (2007) p53 enters the microRNA world. Cancer Cell 12: 414-418.
20. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, et al. (2010) Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1446.
21. Parent R, Qu X, Petit MA, Beretta L, (2009) The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. Hepatology 49: 1798-1809.
22. Batts KP, Ludwig J, (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19: 1409-1417.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
24. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003-5008.
25. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W, (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15: 31-33.
26. Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, et al. (2011) Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 31: 474-484.
27. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106: 4402-4407.
28. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56: 1830-1838.
29. Xu J, Wu C, Che X, Wang L, Yu D, et al. (2011) Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50: 136-142.
30. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al. (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol.
31. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107: 264-269.
32. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M, (2011) Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol In press.
33. Negro F, Sanyal AJ, (2009) Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 29 (Suppl 2): 26-37.
34. Sanyal AJ, (2011) Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int 31 (Suppl 1): 23-28.
35. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, et al. (2011) Serum lipids and their associations with viral levels and liver disease severity in a treatment-naive chronic hepatitis C type 1-infected cohort. J Viral Hepat 18: e144-152.
36. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, et al. (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology.
37. Ioannou GN, Boyko EJ, Lee SP, (2006) The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 101: 76-82.